Epivir 150 mg Tablets

Epivir 150 mg tablets and the available choices

Epivir is a brand of lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI) used with other antiretroviral medicines to treat HIV infection. The concrete product covered by this guide is an oral tablet containing 150 mg of lamivudine. All Epivir options in our current range have the same active ingredient, strength and dosage form, so the main product choice is the number of tablets rather than a choice between different strengths or formulations.

We offer six quantities: 30, 60, 90, 120, 180 and 240 tablets. That range allows customers to compare a smaller supply with quantities intended to cover a longer part of an established treatment plan. Package size should still reflect the prescription, expected use, follow-up arrangements and any possibility that the treatment plan may change. The purpose of this guide is to explain those practical differences without treating the largest quantity as automatically preferable.

Comparing package sizes and unit value

Package price and cost per tablet can vary with quantity. The comparison below contains our current package options, exact prices, per-tablet values and relative savings. It is the appropriate place to compare the figures because prices can change, and no assumptions about competitor prices, local pharmacy prices or general market averages are needed.

Unit value is useful, but it should be considered alongside medical suitability. A lower cost per tablet has practical value only when the quantity is consistent with the prescribed supply and the tablets are likely to be used before their expiry date. A smaller quantity may be more appropriate when treatment is being reviewed or changed. A larger quantity may be practical for an established prescription, but its unit price alone is not a reason to order more medicine than required.

When comparing options, check the total package price as well as the per-tablet figure. The lowest total outlay and the lowest unit cost answer different questions: one concerns the immediate order cost, while the other concerns the average cost of each tablet. Neither measure replaces advice from the authorised prescriber responsible for the treatment plan.

How many tablets should you order?

The appropriate quantity depends on the prescribed supply rather than a universal rule. HIV treatment is generally ongoing, but prescriptions, monitoring schedules and combination regimens can change. It is therefore better to base an order on the current treatment plan than to describe a package as a standard starter or continuation pack when no such designation has been supplied for these options.

• Confirm that the prescription is for Epivir or lamivudine 150 mg oral tablets and check the quantity authorised.
• Consider when the next clinical review, pathology test or prescription renewal is expected.
• Check whether any medicine in the combination regimen is likely to be reviewed at a different time.
• Make sure the tablets can be stored correctly and are expected to remain within their expiry date.
• Compare the total price and unit value only after confirming that the quantity is medically and practically suitable.

A smaller package can limit unused medicine if a prescriber expects to review the regimen soon. A larger package can reduce the frequency of repeat orders when the prescription and treatment plan support that quantity. These are practical considerations rather than dosing recommendations. Do not change the dose, dosing frequency or duration to make a particular package last longer.

Brand, generic and related antiviral context

Epivir is the brand name, while lamivudine is its active ingredient. A generic lamivudine tablet may contain the same active ingredient and strength, but brand and generic products should not be substituted solely on the basis of price without checking the prescription and professional advice. Packaging, tablet appearance and inactive ingredients can differ even when the active ingredient is the same.

Lamivudine is also used for hepatitis B under other product names and at different doses. Those products are intended for a distinct condition and should not be treated as equivalent to Epivir 150 mg tablets for HIV treatment. The indication, strength and regimen all matter when identifying the correct product.

For broader context, customers can browse medicines associated with HIV and our wider Anti Viral & Immunity category. Other antiretroviral medicines may form part of a combination regimen, but they are not direct package-size alternatives to Epivir and should not be exchanged without prescriber involvement.

What role does Epivir have in HIV treatment?

Epivir 150 mg tablets are used to treat HIV infection in combination with other antiretroviral medicines. Lamivudine is not normally used alone for HIV because a multi-medicine regimen provides more reliable viral suppression and reduces the likelihood of resistance developing. The exact combination depends on factors such as previous treatment, resistance results, kidney function, other health conditions and possible medicine interactions.

Antiretroviral treatment controls HIV replication but does not cure HIV. Effective ongoing treatment can reduce the amount of virus in the blood and support immune function. The treating clinician determines the appropriate combination and monitoring plan. Customers should not add Epivir to another regimen or replace one antiretroviral medicine with it simply because a particular package or price appears suitable.

How lamivudine works and is used

HIV uses an enzyme called reverse transcriptase to copy its genetic material. Lamivudine is converted inside cells into an active form that interferes with this process. By interrupting the formation of viral DNA, it reduces the production of new virus and supports the action of the other medicines in the regimen.

Epivir tablets are swallowed and may generally be taken with or without food. The dose and schedule must follow the prescription because individual treatment can be affected by factors such as kidney function and the other medicines being taken. This guide does not establish an individual dose or suggest that the available package quantities correspond to particular treatment durations.

Consistent use is important in HIV treatment. Missed doses or stopping treatment without medical advice may allow viral replication to increase and can contribute to resistance. If a dose is missed, follow the instructions supplied with the medicine or ask the prescriber or pharmacist what to do. Do not double a dose unless specifically instructed by an appropriate health professional.

Safety, side effects and interactions

Lamivudine can cause side effects, although not everyone experiences them. Report persistent or concerning symptoms to the treating clinician. Urgent medical attention is appropriate for signs of a severe allergic reaction or other serious symptoms. Known hypersensitivity to lamivudine or any tablet ingredient is a contraindication.

• People with diabetes may need closer monitoring because combination antiretroviral therapy can be associated with metabolic changes, including insulin resistance and raised blood glucose.
• Use during pregnancy requires an individual benefit-and-risk assessment by the treating clinician. Do not stop effective HIV treatment because of pregnancy without specialist advice.
• Lamivudine passes into breast milk. Australian product information advises mothers with HIV who are taking lamivudine not to breastfeed, including because of the risk of HIV transmission.
• Paediatric dosing is based on body weight. The 150 mg tablet is suitable only for specified weight groups and is not suitable for children weighing less than 14 kg.
• Dizziness or fatigue may affect some people. Consider the medicine's effects and the underlying condition before driving or operating machinery.

Tell the prescriber and pharmacist about all prescription medicines, non-prescription medicines and supplements being used. In particular, another product containing lamivudine could duplicate the active ingredient. Emtricitabine is closely related to lamivudine and is not normally combined with it. Trimethoprim, including in trimethoprim-sulfamethoxazole products, can increase lamivudine exposure and may require clinical consideration, especially when kidney function is reduced. These points do not constitute a complete interaction list.

Store the tablets at 25°C. Temporary exposure to temperatures from 15°C to 30°C is permitted. Keep medicines out of the reach of children and check the packaging for the expiry date and any additional storage instructions.

Is a prescription needed in Australia?

Epivir 150 mg film-coated tablets containing lamivudine are registered in the Australian Register of Therapeutic Goods. Lamivudine 150 mg tablets are prescription-only medicines in Australia and require authorisation from an appropriate prescriber. That legal classification is separate from an online retailer's order-submission procedure.

Under our current ordering policy, we do not require customers to submit a prescription when placing an order. This administrative policy does not remove the Australian prescription requirement or make Epivir appropriate for self-directed treatment. Customers in Australia should obtain and use lamivudine under the care of an authorised prescriber, with the clinical monitoring required for HIV treatment.

Eligible patients may also have access to lamivudine through Pharmaceutical Benefits Scheme arrangements for highly specialised medicines, subject to the applicable restrictions and prescriber requirements. That pathway is separate from our displayed package prices and should be discussed with the treating service when relevant.

Ordering, support and delivery

After confirming the product and an appropriate quantity, select the required package option and review the current total at checkout. We display the available quantities and their prices so that customers can compare the immediate order cost with the per-tablet value shown in the package comparison. We do not use unsupplied competitor prices, local pharmacy prices or market averages to support the choice.

• Check that the selected product is Epivir 150 mg oral tablets.
• Choose only a quantity consistent with the authorised treatment and expected use.
• Review the order and delivery details carefully, including the Australian destination and postcode.
• Use email, online chat or phone to contact our support team if an order or product detail needs clarification.
• After confirmation, we pack the order, prepare it for dispatch and provide the available delivery updates.

Our support channels are available 24/7, and pharmacist support is available for general medicine and product questions. This support can help clarify matters such as the listed strength, dosage form, storage requirements or package options, but it does not replace the prescriber who determines an individual's regimen or authorised quantity.

A balanced package-value decision

The six Epivir options contain the same 150 mg strength in the same oral tablet form. The meaningful commercial comparison is therefore between package quantities, total prices and per-tablet values. The package-value element near the beginning provides the current figures without relying on external price claims.

A sound choice starts with the prescription and expected use, then considers review timing, storage, expiry and order frequency. The lowest unit price may be attractive, but it is not valuable if the quantity exceeds what is authorised or likely to be used. Conversely, the package with the lowest total price may require more frequent ordering. Comparing both measures makes the trade-off clearer without turning price into medical advice.

Before ordering, confirm the exact product identity: Epivir, lamivudine 150 mg, oral tablets for use as part of combination HIV treatment. Once that is established, use the live comparison to select an appropriate available quantity. Our team can clarify catalogue and order information, while dosing, treatment duration and regimen changes remain matters for the authorised prescriber.